Heparin more precisely called unfractionated heparin, is a naturally occurring glycosaminoglycan and also an anticoagulant that is used for the prevention as well as treatment of thrombotic events like deep vein thrombosis (DVT) and pulmonary embolism (PE). Heparin is also used during cardiac surgery to prevent excess coagulation. Heparin also plays an important role in renal replacement therapy thus preventing coagulation. Heparin is also used for treatment in other thrombotic states like atrial fibrillation undergoing cardioversion, systemic emboli, etc. The dose of heparin differs depending on the indication. In obese patients, maximum bolus infusion and continuous infusion rate are maintained.
Heparin when administered in the circulation, binds with various proteins, mainly antithrombin. Antithrombin is a glycoprotein that inactivates several enzymes that are involved in the clotting mechanism of the human body. Thus, binding with antithrombin leads to blockage of several different clotting factors, two of which are the prominent ones, Factor IIa and Factor Xa. Thus, due to the blockage of these factors, fibrinogen is unable to convert into fibrin. Thus, the process of blood clotting is prolonged. Heparin here does not completely stop the clotting of blood or affect the bleeding time, it simply prolongs the clotting time of the blood. Heparin could be administered by intravenous (IV) route as well as subcutaneous (SQ) route.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/heparin-market/
Global Heparin Market – Competitive Insight
In April 2020, Hepalink bought SPL for USD 337 million for the supply of heparin product raw materials.
Some of the Global Heparin Market Include –
- Pfizer Inc.
- Fresenius SE & Co. KGaA
- Bioiberica SA
- Biomedical Foscama Group
- Biovet SA
- Changzhou Qianhong Bio-pharma Co. Ltd.
- Reddy’s Laboratories
- CSPC NBP Pharmaceutical Co. Ltd.
- Gelita Medical AG
- Intas Pharmaceuticals Ltd.
- Nanjing King-friend Biochemical Pharmaceutical Co. Ltd.
- Pharma Action Ltd.
- Rovi Pharma Industrial Services Ltd.
- Sagent Pharmaceuticals Inc.
- Aspen Pharmacare Holdings Limited
- B Braun Melsungen AG
- Baxter International Inc
- Hebei Changshan Biochemical Pharmaceutical
- Leo Pharma AS
- Opocrin SpA
Global Heparin Market – Growth Drivers
There has been a constant increase in the events of chronic diseases like coronary artery disease and chronic kidney disease. According to The Global Burden of Diseases, Injury, and Risk Factors study in 2019 8.9 million women and 9.6 million men died due to cardiovascular diseases, and of which more than 6 million were between the ages of 30-70. This data indicates that it is likely that the cases of cardiovascular diseases will increase as a result of population growth and aging. Thus the above factors will help in the growth of the global heparin market. It has also been observed that there is an increase in the geriatric population i.e. the elderly population. A report from WHO states that by 2030, 1 in every 6 people in the world will be aged 60 or above. WHO also estimates that the geriatric population will increase from 1 billion in 2020 to 1.4 billion in 2050. This data clearly explains why chronic diseases will increase in the future, thus being the growth driver for the global heparin market. Moreover, the funding of the government in an increase of health services also is a growth driver for the heparin market.
Global Heparin Market – Restraints
Despite the anticoagulant activity of heparin, there are many side effects of heparin. According to an article published by NIH, bleeding is the major complication of heparin. Hemorrhagic complications due to heparin may be fatal and life-threatening. Accidental bleeding may occur at surgical sites or open wounds. These factors cause the depletion in the use of heparin. Moreover, thrombocytopenia occurs in up to 30% of the patients who receive heparin during their treatment. Heparin-induced thrombocytopenia (HIT) is more serious in the case of heparin administration thus being another restrain for the particular market. Various substitutes for heparin are induced in the market. According to an article in Oxford Academic, Argatoban as a substitute for heparin in cardiopulmonary bypass surgery is discussed. Thus, the substitutes of heparin as an anticoagulant is another point that may restrain the global heparin market.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/heparin-market/
Global Heparin Market – Opportunities
According to the WHO estimate the geriatric population will increase from 1 billion in 2020 to 1.4 billion in 2050. Thus, increase in the geriatric population also in turn means an increase in cardiovascular complications. Therefore, use of heparin in the treatment of complications also increases. Thus there a constant growth opportunities in the heparin market. Moreover, the inclusion of low molecular weight heparin (LMWH) also provides future opportunities in the particular market. Rise in health awareness and expenditure are expected to propel the heparin market. In the Covid-19 period, heparin was primarily used as an anticoagulant along with other therapies. The use of heparin has increased since the Covid-19 period. Thus, there stands an opportunity for the heparin market as heparin is primarily used as an agent to prevent coagulopathy.
Global Heparin Market – Geographical Insight
The market for dry eye disease is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & Africa. North America is the largest market for heparin due to well-established healthcare infrastructure facilities and widespread diagnosis and treatment. Europe is expected to be the other prominent heparin market. Growth in the infrastructure in the health industry is the primary reason. Asia Pacific is another prominent market. The reason is an increase in the number of the elderly population which in turn leads to an increase in the opportunities for the global heparin market.
Global Heparin Market – Key Development
- Feb 13, 2024, B. Braun launched Heparin Sodium 2,000 units in 0.9% NaCl injection. This heparin is manufactured using EXCEL IV containers.
- On April 21, 2021, Fresenius Kabi introduced its Concentration of Heparin Sodium in convenient and ready-to-administer Freeflex IV bags.